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Treatment of chronic graft-versus-host disease is intended to produce a sustainable beneﬁt by reducing
symptom burden, controlling objective manifestations of disease activity, preventing damage and impair-
ment, and improving overall survival without causing disproportionate harms related to the treatment itself.
Successful management can control the disease until systemic treatment is no longer needed. The complexity
of the disease, the extended duration of follow-up needed to observe disease resolution and withdrawal of
immunosuppressive treatment, and the lack of fully developed shorter term endpoints impede progress in
the ﬁeld. Identiﬁcation and characterization of primary endpoints demonstrating clinical beneﬁt without
requiring years of follow-up is urgently needed, with the understanding that clinical beneﬁt encompasses not
only the self-evident beneﬁt of the primary endpoint but also any other associated beneﬁts. This report
discusses regulatory considerations, eligibility criteria, the value of controlled trial designs, the merits of
proposed primary endpoints, and key considerations elaborated from experience and progress during the
past decade. The report concludes by mapping an overall approach that could support and lead to maximally
informative clinical trials, especially those that seek to demonstrate clinical beneﬁt along a pathway to
regulatory review and approval.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Effective treatment for chronic graft-versus-host disease
(GVHD) is an urgent unmet clinical need. The number of
pharmaceutical companies interested in developingdgments on page 1357.
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ty for Blood and Marrow Transplantation.products for chronic GVHD increased markedly since the
previous National Institutes of Health (NIH) Consensus
Conference. In April 2015, ClinicalTrials.gov listed 9 industry-
sponsored studies open for recruitment to evaluate systemic
products for treatment of chronic GVHD. Progress is
hampered by the lack of deﬁned pathways for clinical
development and regulatory approval of products intended
for treatment of chronic GVHD. Regulatory applications are
most likely to be submitted as new indications for products
previously approved for other indications, but in certain
P.J. Martin et al. / Biol Blood Marrow Transplant 21 (2015) 1343e13591344cases they could be ﬁled for new products to treat or prevent
chronic GVHD. Relevant considerations include a plausible
mechanism of action; demonstrated anti-inﬂammatory,
immunosuppressive, or antiﬁbrotic activity; and the safety
proﬁle.
The number of patients available for enrollment in
chronic GVHD treatment trials is limited. Among the
approximately 8000 allogeneic hematopoietic cell trans-
plantations performed each year in the United States [1], at
least 35% of recipients would be expected to develop chronic
GVHD requiring systemic treatment [2], such that the total
incidence is approximately 3000 per year. The total preva-
lence in the United States is estimated at approximately
10,000, after accounting for durable disease resolution and
end of treatment together with deaths and recurrent ma-
lignancy during treatment [3]. Although the incidence of
steroid-refractory chronic GVHD is lower than the overall
incidence of chronic GVHD, the prevalence of steroid-
resistant or steroid-refractory chronic GVHD is difﬁcult to
estimate. This limited pool of potential study candidates
suggests that major questions can be addressed most efﬁ-
ciently by multicenter or cooperative group trials.
Controlled designs have been used for only a small mi-
nority of chronic GVHD treatment trials. The 6 published
randomized trials of ﬁrst-line treatment for chronic GVHD
used a variety of primary endpoints, and none demonstrated
superiority of the investigational arm [4-9]. The design of
controlled second-line treatment studies is hampered by the
lack of a standard treatment regimen. Only 1 randomized
trial of second-line treatment for chronic GVHD has been
published [10,11].
Uncontrolled, single-arm studies of second-line treat-
ment typically show overall response rates of 30% to 70%
[12]. In many studies response criteria are poorly deﬁned,
and results are interpreted under the premise that no
response would have occurred in the absence of the inves-
tigational treatment. This premise might not hold true,
especially if the prior trajectory of GVHD is not taken into
account, if active topical agents are added, if doses of prior
medications are increased, or if systemic agents other than
the investigational product are added between enrollment
and the response assessment. These factors, together with
variation in selection criteria, patient characteristics, base-
line disease manifestations, and assessment time points,
make it difﬁcult to interpret the results of single-arm studies
of second-line treatment or to establish reliable benchmark
response rates for planning future studies [12].
PURPOSE OF THIS DOCUMENT
The complexity of chronic GVHD and the lack of fully
developed research methods make it difﬁcult to design,
conduct, and analyze clinical trials involving subjects with
this disease, even when promising treatment options are
available. The 2006 Design of Clinical Trials Working Group
Report [13] offered important recommendations and deﬁ-
nitions for investigators in an attempt to overcome these
obstacles. The Working Group anticipated that the use of
consistent standards in clinical trial designs to evaluate
agents that have activity in pathogenic pathways could
facilitate advances in the treatment of chronic GVHD.
Work during the decade since the previous NIH
Consensus Conference yielded improvements in the preci-
sion and accuracy of criteria for the diagnosis and staging of
chronic GVHD [14], the interpretation of histopathology [15],
the discovery and validation of biomarkers for diagnostic andprognostic applications [16], and supportive care for patients
with chronic GVHD [17]. These results set the stage for much
needed progress in the deﬁnition of response criteria and the
design considerations to be applied in clinical trials testing
the efﬁcacy and safety of products for treatment of chronic
GVHD. A separate report describes progress toward the
development of the most clinically relevant response criteria
[18]. The current report focuses on considerations for the
design of clinical trials.
Although the original recommendations from the 2006
Design of Clinical Trials Working Group Report [13] were
broad-based and grounded in good clinical practice, further
improvement is needed. The current report is focused pri-
marily on the development, characterization, validation, and
selection of primary and secondary endpoints that could be
used to demonstrate clinical beneﬁt without requiring years
of follow-up, thereby mapping an overall approach that
could support regulatory review. Prior recommendations
that merit updating or attention based on experience since
the previous NIH Consensus Conference are also highlighted
and elaborated.
This report does not address considerations for the design
of trials for prevention of chronic GVHD. The development of
designs and regulatory paths are more advanced for pre-
vention trials than for treatment trials. Sponsors and in-
vestigators of chronic GVHD prevention studies are
encouraged to use information from the NIH Consensus
Development Project on Criteria for Clinical Trials in Chronic
GVHD in deﬁning diagnostic [14] and pathological criteria
[15] and in applying biomarkers [16] in clinical trials.
SUMMARY OF UPDATED RECOMMENDATIONS
1. Primary and secondary endpoints should be selected
for their ability to demonstrate clinical beneﬁt, which
can be a prolongation of survival or an improvement in
the way a patient feels or functions. The overall
concept of clinical beneﬁt encompasses not only the
self-evident beneﬁt of the primary endpoint per se but
also any tangible and measurable beneﬁts in symptom
burden, quality of life, or other important outcomes
demonstrated to be closely associated with the pri-
mary endpoint. Patient-reported measures should be
incorporated whenever feasible. Standardized and
clinically valid measurements should be used. Com-
posite endpoints may be required in some protocols.
2. Many endpoints are clinically meaningful, but the
number of patients available to participate in chronic
GVHD treatment trials is small. Therefore, studies
should be designed to capture as much relevant in-
formation as possible from providers and patients,
even if the data will not be submitted for regulatory
review.
3. Inclusion and exclusion criteria should ensure the
ability to interpret results of the study while as much
as possible allowing enrollment of patients who might
beneﬁt, based on the investigational product’s mech-
anism of action.
4. Baseline evaluations should document eligibility, cap-
ture prognostic characteristics, and speciﬁcally char-
acterize the condition of subjects at the time of
enrollment so results of therapy can be interpreted.
5. Within reason, the study protocol should specify or
provide guidance regarding the dosing and dose
adjustment of all immunosuppressivemedications and
Figure 1. Appropriate management of chronic GVHD requires continuous
recalibration of immunosuppressive treatment to avoid over- or under-
treatment. The intensity of treatment required to control the disease de-
creases across time. Manifestations of chronic GVHD improve or are absent
when the intensity of treatment (- - -) is above the threshold (shown as the
orange curve) and worsen or recur when the intensity of treatment is below
the threshold. The slope of the threshold varies among patients and can be
determined only by serial attempts to decrease the intensity of treatment.
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products. Reasons for deviations, discontinued
administration or use of the study product, and new
treatment should be documented in case report forms.
6. Case report forms should be calendar driven by the
protocol to provide assessment of chronic GVHD and
adverse events at regular intervals. Study personnel
should conduct real-time cleaning and monitoring of
baseline and response assessments to ensure accurate,
consistent evaluations.
7. Biostatistical analysis should incorporate consider-
ations of competing events, such as recurrent malig-
nancy or nonrelapse mortality, and any new
concomitant systemic or topical therapy started at the
time of enrollment or afterward. The protocol should
provide appropriate power calculations and
summarize statistical plans for any interim analyses,
sensitivity analysis, subset analysis, and missing
measurements.
8. Controlled designs are preferred whenever possible,
because they allow interpretation of the treatment
effect (ie, efﬁcacy and safety), if prognostic risk factors
are balanced between the arms. Stratiﬁcation can be
used to decrease the risk of imbalanced distribution of
risk factors in controlled trials. Treatment effects are
very difﬁcult to interpret single-arm studies.Successful management of chronic GVHD can control the disease until
systemic treatment is no longer needed to prevent recurrent or progressive
disease activity or exacerbation of any residual damage (.......).GOALS OF TREATMENT FOR CHRONIC GVHD
Treatment of chronic GVHD is intended to produce a
sustainable beneﬁt by reducing symptom burden, control-
ling objective manifestations of disease activity, preventing
damage and impairment, and improving overall survival
without causing disproportionate harms related to the
treatment itself. Early experience showed that in the absence
of systemic treatment, chronic GVHD progresses inexorably
to disability and death [19]. Management of chronic GVHD
has relied on corticosteroids as the mainstay of treatment for
more than 3 decades, although treatment regimens vary
[20-22]. Systemic treatment typically begins with predni-
sone at .5 to 1 mg/kg/day, with or without cyclosporine,
tacrolimus, or sirolimus. Prolonged treatment with predni-
sone at high doses causes many adverse effects, making it
necessary to taper the dose as soon as GVHD improves.
Manifestations of chronic GVHD can wax and wane when
efforts are made to reduce or closely calibrate the intensity of
immunosuppressive treatment to the minimum needed to
control the disease (Figure 1). In a prospective study, the
average dose of prednisone was tapered to .20 to .25 mg/kg/
day or to .4 to .5 mg/kg every other daywithin 3months after
starting systemic treatment [8].
Successful management of chronic GVHD can control the
disease until systemic treatment is no longer needed to
prevent recurrent or progressive disease activity or exacer-
bation of any residual damage. After withdrawal of systemic
treatment, laboratory testingmay detect persistent low-level
alloreactivity that is not sufﬁcient to cause progression in any
residual clinical manifestations of the disease. Systemic
treatment is discontinued in approximately 50% of patients
within 7 years after starting systemic treatment. Approxi-
mately 10% of patients require continued systemic treatment
for an indeﬁnite period beyond 7 years, and the remaining
40% develop recurrent malignancy or die from nonrelapse
causes while continuing systemic treatment within 7 years
after diagnosis [3]. Discontinuation of systemic treatmentmight not be possible for some patients with far advanced
chronic GVHD that has persisted despite the use of multiple
immunosuppressive agents for many years. In these cir-
cumstances, the goals of treatment are to control symptoms
and disease activity; to prevent further damage and impair-
ment, whether from the disease itself or from the medica-
tions used for management; and to improve survival.
It is not known whether currently available immuno-
suppressive products shorten or lengthen the time to with-
drawal of treatment. In either case, they provide clinical
beneﬁt by controlling disease activity and preventing
impairment until systemic treatment can be discontinued. In
this context, new products for treatment of chronic GVHD
could increase clinical beneﬁt if they are more effective than
currently available treatments without causing a dispropor-
tionate burden of side effects or if they are as effective as
currently available treatment but cause a lesser burden of
side effects.
REGULATORY CONSIDERATIONS FOR CHRONIC GVHD
CLINICAL TRIAL DESIGN
Many important clinical trials, including some that
changed the standard practice in the ﬁeld of hematopoietic
stem cell transplantation, were not done with the objective
of approving a new drug or a new indication for an already
approved drug. On the other hand, commercial sponsors are
key stakeholders in the development of new therapies for
treatment of chronic GVHD, and if progress is to be made in
this area, clinical trial designs must address the regulatory
requirements that commercial sponsors must meet. Overall
survival and survival to durable resolution of chronic GVHD
with withdrawal of all systemic treatment are endpoints that
clearly indicate clinical beneﬁt in regulatory terms, but the
long follow-up time needed to ascertain these endpoints
makes them challenging for use in chronic GVHD drug
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by the Clinical Trials Design Working Group include clinical
response, failure-free survival (FFS), survival without pro-
gressive impairment (SWOPI), patient-reported outcomes
(PROs), and composite scales that incorporate provider and
patient assessments.
In preparing the current report, members of the Clinical
Trials Working Group met with representatives of the US
Food and Drug Administration (FDA) to discuss the regula-
tory perspectives on proposed endpoints. Brieﬁng materials
used for this meeting summarize current knowledge about
potential endpoints in chronic GVHD trials (see online
supplement at http://www.asbmt.org/?page¼PIND124475).
Key general advice provided by the FDA included the
following:
 Endpoints may differ based on the natural history of the
intended population as determined by the eligibility
criteria. A survival beneﬁt might need to be demon-
strated when the intended patient population has a
relatively short expected overall survival, whereas for
patients who live long but with the potential for
disability (most patients with chronic GVHD in the
modern era), a clinician-reported outcome (CRO) or
PRO might be more appropriate.
 A CRO or PRO assessment might be acceptable as a
measure of clinical beneﬁt without validation against
survival. The tool should be well deﬁned and reliable. A
PRO should be supported by an objective clinical mea-
sure of drug activity, such as complete plus partial
response.
 A composite endpoint would be acceptable if each
component could be justiﬁed, but sample size consid-
erations or characteristics of the intended patient
population may warrant a simpler endpoint or copri-
mary endpoints instead.
 A composite endpoint that includes efﬁcacy and safety
outcomes would not be sufﬁcient to demonstrate efﬁ-
cacy, because differences in safety might obscure dif-
ferences in efﬁcacy.
 Use of progression-free survival (PFS) types of chronic
GVHD clinical endpoints for a regulatory decision must
be meaningful for the particular study population.
Whether a PFS endpoint is meaningful depends on
relevance of the criteria for PFS to direct clinical beneﬁt,
the magnitude of the effect, and the riskebeneﬁt of the
new treatment.
 Time-to-event endpoints commonly used in random-
ized trials, such as PFS, are generally not interpretable
in single-arm trials, especially with patient populations
heterogeneous for factors that may affect the endpoint.
In the sections that follow, the Clinical Trials Working
Group discusses key aspects of eligibility criteria, types of
comparators, and the proposed endpoints and reﬂects on
when and how these regulatory considerations might affect
the clinical trial design.
ELIGIBILITY CRITERIA AND DATA CAPTURE
Well-deﬁned eligibility criteria are needed for all trials.
Inclusion criteria depend on the speciﬁc medical indication
for treatment. For chronic GVHD treatment trials, possible
intended uses include global systemic effect, effect on a
speciﬁc systemic manifestation such as ﬁbrosis, or local ef-
fect on speciﬁc organs such as pulmonary disease. Exclusioncriteria have several purposes, including the protection of
patients who could be harmed by participation in the study
and elimination of factors that could confound the inter-
pretation of results. At the same time, eligibility criteria
should be designed so that enrolled patients are represen-
tative of patients with the intended indication.
Standardized assessment forms used at baseline and
follow-up should contain sufﬁcient detail to verify the
diagnosis of chronic GVHD and establish eligibility. The level
of detail should also be sufﬁcient to determine global
severity according to updated NIH criteria, because global
severity is associated with overall survival and the risk of
nonrelapse mortality [23]. In addition, reﬁnements proposed
by the 2014 Diagnosis and Staging Working Group capture
data indicating whether individual organ scores should be
attributed to GVHD [14]. Baseline data for CRO and PRO
endpoints should be collected before randomization to
ensure the absence of bias. As a key lesson from recent
experience, study personnel should conduct real-time
cleaning and monitoring of baseline data and follow-up
response assessments. Delayed reconciliation between
medical records and case report forms and other data
cleaning make it extremely difﬁcult to rectify omissions or
inconsistencies across the various multiorgan assessments.
Eligibility criteria for speciﬁc trials may vary according to
whether or not patients require treatment change. Enroll-
ment in ﬁrst- and second-line systemic treatment trials is
motivated by the immediate need to relieve symptoms,
control disease activity, prevent damage and impairment,
and, if possible, shorten the time to withdrawal of systemic
treatment. New onset of chronic GVHD prompts the need for
ﬁrst-line treatment, and unsatisfactory response to previous
treatment prompts the needs for second-line treatment. In
second-line treatment trials, the minimum dose and dura-
tion of prior treatment and the minimum severity of unim-
proved disease manifestations or criteria for worsening must
be deﬁned, although medical records may lack optimal
documentation of this information. Clinical trials may also be
designed for patients with stable chronic GVHD manifesta-
tions. For these trials, documentation of stable disease
manifestations and treatment across some minimum time
interval before enrollment is required.
Standardized deﬁnitions of steroid-refractory and
steroid-dependent chronic GVHD in determining eligibility
for enrollment would facilitate comparisons between results
of different studies, but practices vary considerably, making
it difﬁcult to reach consensus. This Working Group offers the
following deﬁnitions and considerations for second-line
treatment trials:
 Steroid-refractory chronic GVHD during ﬁrst-line
treatment may be deﬁned when manifestations prog-
ress despite the use of a regimen containing prednisone
at 1 mg/kg/day for at least 1 week or persist without
improvement despite continued treatment with pred-
nisone at .5 mg/kg/day or 1 mg/kg every other day for
at least 4 weeks.
 Steroid-dependent chronic GVHDmay be deﬁnedwhen
prednisone doses > .25 mg/kg/day or >.5 mg/kg every
other day are needed to prevent recurrence or pro-
gression of manifestations as demonstrated by unsuc-
cessful attempts to taper the dose to lower levels on at
least 2 occasions, separated by at least 8 weeks. These
suggested dose thresholds match the average doses
from 3 months onward in a prospective study of
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appropriate depending on the trial context and should
be speciﬁed in the protocol.
Three important caveats apply for these deﬁnitions. First,
they are far less relevant to eligibility criteria for trials
beyond second-line treatment, because the transition be-
tween ﬁrst-line and second-line treatment has already
established that the disease is steroid-refractory or steroid-
dependent. In this scenario, appropriate eligibility criteria
could be based on clinical judgment that the disease is re-
fractory to the current treatment regimen. Second, they serve
as general guidelines inwriting eligibility criteria for second-
line treatment trials but do not completely match clinical
practices [24]. For example, some patients advance to
second-line treatment after ﬁrst-line treatment with pred-
nisone that never exceeded .5 mg/kg/day or after complete
withdrawal of prior systemic treatment. Small numbers of
patients begin second-line treatment because of progressive
disease after less than 7 days of ﬁrst-line treatment or
because of insufﬁcient improvement after less than 4 weeks
of ﬁrst-line treatment. Although no consensus has been
reached for these situations, second-line treatment protocols
should address the required minimum dose and duration of
prior steroid treatment, because these parameters might
relate to the lack of an adequate response during ﬁrst-line
treatment. Third, steroid intolerance alone is not a sufﬁ-
cient reason to enroll a patient in a trial intended to evaluate
an investigational product for treatment of steroid-refractory
or steroid-dependent chronic GVHD.
When a reduction in symptoms based on a PRO is the
primary objective, attention should be paid to the minimum
burden of symptoms at baseline for eligibility to ensure a
clinically meaningful reduction can be measured. Similarly,
for studies that seek to prevent progression of symptoms, the
eligibility criteria should ensure the baseline symptom
burden of study participants is not so great that worsening
could not be detected.
The role of biomarkers in deﬁning eligibility for clinical
trials is not established. Validated biomarkers that reliably
reﬂect the severity of chronic GVHD manifestations, indicate
the prognosis for patients with chronic GVHD, or predict the
likelihood of response to treatment would be very useful in
the design and conduct of clinical trials [16]. Objective
laboratory-based biomarkers strongly correlated with dis-
ease activity and measured with standardized assays would
be very useful in comparing the baseline characteristics of
patients enrolled in different studies.
CONTROLLED DESIGNS
Single-arm studies are not interpretable for regulatory
purposes, especially if the population has heterogeneity in
prognostic factors. The heterogeneity of the disease process
and the patients affected means that differences between
single-arm studies may be due solely to population differ-
ences rather than treatment effects. Blinded randomized trial
designs help to prevent bias in the assessment of such end-
points, but these designs are not always feasible. For open-
label trials, a highly robust, well-characterized, objective
primary endpoint and related supporting secondary end-
points are generally needed for adequate interpretation.
In controlled studies of investigational products intended
for ﬁrst-line systemic treatment, 1 arm could receive the
investigational product plus conventional treatment,
whereas the other arm receives conventional treatmentalone. Designs in which 1 arm receives an investigational
product without conventional treatment and 1 arm receives
conventional treatment are also feasible [25]. In controlled
studies of investigational products intended for second-line
systemic treatment in patients who need an immediate
treatment change, 1 arm would receive the investigational
product. Because no standard of care has been established for
this indication, the other arm could receive any other treat-
ment considered within the scope of usual practice, although
some restriction in control treatments might be desirable. In
controlled studies of investigational products intended for
systemic control of chronic GVHD in patients who do not
need an immediate treatment change, 1 arm could receive
the investigational product, whereas the other arm con-
tinues the baseline management.
In any of these approaches, studies could include “in-
duction” and “maintenance” phases with different doses of
the same investigational product or with the sequential use
of different products. Similar considerations apply in studies
of investigational products intended for effect at a speciﬁc
site or on a speciﬁc organ or manifestation of chronic GVHD.
ENDPOINTS
The primary endpoint in a clinical trial represents the
major criterion by which success of the investigational
product will be determined, but it is far from the only cri-
terion in judging the merits of an intervention. The primary
endpoint should reﬂect clinical beneﬁt, deﬁned as surviving
longer or living with fewer symptoms or improved function.
The overall concept of clinical beneﬁt encompasses not only
the self-evident beneﬁt of the primary endpoint per se but
also any other beneﬁts closely associated with the primary
endpoint. For example, a full understanding of the clinical
beneﬁt of “response” requires characterization of the extent
to which a deﬁned type of response is associated with im-
provements in the overall burden of symptoms, level of
function, overall survival, and any other relevant outcomes of
importance and value to patients with chronic GVHD. Clin-
ical beneﬁts that are not self-evident in the primary endpoint
could be understood as “collateral” beneﬁts in the sense that
they coincide with or serve to support or corroborate the
self-evident beneﬁt of the primary endpoint.
Overall success with the primary endpoint is deﬁned in
statistical terms, based on a prespeciﬁed null hypothesis, an
alternative, and the corresponding requisite sample size that
affords adequate statistical power and a 2-sided false-
positive rate conventionally set at 5% or less. The null hy-
pothesis is typically set by the standard of care. In successful
trials, secondary endpoints provide necessary additional
evidence of beneﬁts, and safety endpoints provide evidence
that the overall beneﬁts exceed harms. A successful trial
would show that the beneﬁts of a high response rate are not
offset by reduced overall survival.
The 2006 NIH Consensus Conference on Chronic GVHD
Design of Clinical Trials Working Group Report addressed a
variety of technical and quality considerations in the design
and conduct of clinical trials testing products for treatment of
chronic GVHD [13]. Potential short-term primary and sec-
ondary endpoints discussed in the report included GVHD
response and PROs. The report noted that scales for mea-
surement of global response were not yet validated and that
few sensitive instruments are available for measuring PROs.
As summarized in Table 1, GVHD response was considered
most appropriate as a primary endpoint in phase II studies
and possibly in selected phase III studies, whereas PROs were
Table 1
Endpoint Recommendations in the 2005 Working Group Report
Time Horizon Primary Endpoint Secondary Endpoints
Short GVHD response PROs
Long Complete response
End of systemic treatment*
Nonrelapse mortality
Survival without
recurrent malignancy
Overall survival
* Resolution of chronic GVHD and durable withdrawal of systemic
treatment without subsequent recurrence or progression of disease activity
or exacerbation of any residual damage.
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beneﬁt associated with these endpoints has not been
adequately characterized. These shorter term endpoints are
preferable for early phase trials, but longer term endpoints
are needed for late-phase trials to demonstrate sustainable
beneﬁt. Complete response and successful withdrawal of
systemic treatment after resolution of the disease were
considered most appropriate as primary endpoints in phase
III studies, whereas nonrelapse mortality, survival without
recurrent malignancy, and overall survival were considered
appropriate as secondary endpoints. Notably, in certain
subsets of patients who have chronic GVHD with a moder-
ately severe global NIH rating, mortality rates are very low
(see online supplement) [23,26], leaving little opportunity to
demonstrate improvement in overall survival.
The proposed endpoints of FFS and SWOPI deﬁne clinical
beneﬁt as the absence of new harm caused by the disease,
whereas complete and partial responses deﬁne beneﬁt as
improvement in manifestations of the disease. PROs capture
patient reports of GVHD symptoms and their degree of
bother. Composite scales capture clinician assessments,
PROs, and laboratory or functional measures in a single
global scale. All 5 endpoints represent relatively short-term
outcomes as compared with the typical 2- to 5-year dura-
tion of treatment needed before the disease resolves with
currently available treatment. Therefore, an important issue
is the extent towhich these short-term endpoints predict the
durability of beneﬁt. Strengths and weaknesses of each
endpoint are summarized in Table 2.
An optimal primary endpoint is based on objective, reli-
able, and veriﬁable criteria. Endpoints other than overall
survival must have face validity indicating that patients live
better with fewer symptoms or improved function as evi-
dence of clinical beneﬁt. For patients with chronic GVHD,
evidence of clinical beneﬁt can come from data demon-
strating that a deﬁned endpoint is associated with decreased
burden of symptoms and symptom bother, better function,
fewer side effects associated with treatment, shorter time to
durable resolution of the disease and withdrawal of systemic
treatment, and improved overall survival. Table 3 summa-
rizes the extent to which each of the 5 endpoints has these
characteristics and demonstrable clinical beneﬁt.Response
Assessment of response compares manifestations of
chronic GVHD for each patient at baseline and at 1 or more
deﬁned subsequent time points. Response should be
measured, documented, and reported in all trials of treat-
ment for chronic GVHD, because response is an important
component of clinical beneﬁt. Protocols and study reports
should provide criteria to deﬁne the baseline severity of
patient-reported symptom burden and physician-assesseddisease activity and damage. Protocols and study reports
should likewise provide criteria to deﬁne the degree of
subsequent change in each of these domains required for
improvement or worsening. Information regarding the tra-
jectory of changes in pulmonary function tests and other
objective measures before enrollment can be used to help
interpret changes that occur after enrollment.
Trials using response as an endpoint should be designed
to measure and document the durability of response and to
determine whether continued treatment is needed to
maintain response. For a variety of reasons, response at any
single time point after enrollment is an incomplete indicator
of clinical beneﬁt. Response should be assessed at multiple
time points to determine whether the beneﬁt is sustained.
Protocols should specify how response should be categorized
when a new local or systemic treatment is added after a
patient has been enrolled but before efﬁcacy is assessed.
Most investigational products are likely to be used in
conjunction with anti-inﬂammatory glucocorticoids and
other agents. Trials using response as an endpoint should be
designed to distinguish the effects of the investigational
product from the effects of concomitant treatment. With
highly heterogeneous study populations, single-arm designs
cannot control and account for the myriad other factors that
could inﬂuence response in a study with response as the
primary endpoint.
Response endpoints should be deﬁned in ways that are
consistently associated with demonstrable clinical beneﬁt. In
patients with chronic GVHD that is unlikely to be cured,
response endpoints should be deﬁned in a way that dem-
onstrates clinically meaningful durable improvement in
disease activity and symptoms. For example, resolution of
oral lichenoid changes in a patient with persistent diarrhea
should not be considered as clinically meaningful improve-
ment, whereas isolated improvement in the mouth that
leads to better nutrition might be considered clinically
meaningful even if other less bothersome manifestations
persist. Likewise, improvements that are not durable should
not be considered as clinically meaningful. For patients with
chronic GVHD characterized by a high risk of mortality, an
association of a response endpoint with prolonged overall
survival could provide evidence of clinical beneﬁt. For
example, changes in the 0 to 3 NIH composite skin score
correlated with both clinician and patient perception of
improvement or worsening, and worsening skin scores at 6
months were associated with decreased overall survival [28].
For patients with chronic GVHD characterized by a low risk
of mortality, an association of a response endpoint with
improved PROs could provide evidence of clinical beneﬁt.
Whether a response endpoint should be deﬁned as complete
response or as complete or partial response depends on the
degree to which the partial response component of the
endpoint is associated with the other beneﬁts seen in pa-
tients with complete response.
Table 4 summarizes results of previous studies investi-
gating clinician-reported measures as potential indicators of
beneﬁt in clinical trials. The provisional criteria proposed by
the 2005 NIH Consensus Conference for measuring treat-
ment response of chronic GVHD were based on expert
opinion [37], and an Excel spreadsheet tool has been devel-
oped to apply these criteria in clinical trials [36]. Responses
deﬁned according to the proposed algorithm correlated with
improved symptom burden but not with improved quality of
life by other measures [38]. Furthermore, agreement be-
tween response and physicians’ clinical assessment was poor
Table 2
Strengths and Weaknesses of 5 Proposed Endpoints in Chronic GVHD Therapy Trials
Proposed
Endpoint
Deﬁnition Statistical Considerations Strengths Weaknesses
GVHD
response
Complete plus partial response
based on clinician- reported
measures
Comparison of proportions with
treatment response at a speciﬁc
time point
Direct measure of success
Lengthy follow-up not needed
Easily applied
Scales not fully qualiﬁed
FFS Survival for a deﬁned period
without new systemic treatment,
death, or recurrent malignancy
Time-to-event or
Comparison of proportions with
FFS at a speciﬁc time point
Benchmarks available for ﬁrst-
and second-line treatment
Correlates with overall
improvement reported by
providers and patients
Correlates with ability to
discontinue systemic treatment
Indirect measure of failure
Improvement is not measured (ie,
GVHD manifestations may
persist)
New treatment decisions are
subject to bias and inconsistency
Not accepted for regulatory
approvals
SWOPI Survival without an enduring
chronic GVHD-related effect that
threatens or compromises
physical well-being or function in
ways that cannot be easily
reversed
Time-to-event, or
Comparison of proportions
surviving without progressive
impairment at a speciﬁc time
point
Failure directly measured
Correlates with overall
improvement reported by
providers and patients
Improvement is not measured (ie,
GVHD manifestations may
persist)
Impairment is not yet fully
deﬁned
Some impairment measures
might not be entirely speciﬁc for
chronic GVHD
Impairment can be caused by
adverse events
PROs Self-reported patient information
on symptoms and
multidimensional quality of life
Comparison of proportions with
clinically meaningful
improvement at a speciﬁc time
point
Comparison of distributions
between study arms
Captures the patient perspective
Lengthy follow-up not needed
Easily applied
Subject to respondent biases
Missing data difﬁcult to control
Claims limited to PROs
Composite
scale
Selected measures from provider
and patient
Comparison of proportions with
clinically meaningful
improvement at a speciﬁc time
point
Comparison of distributions
between study arms
Aggregates data from multiple
perspectives
Scale not developed or qualiﬁed
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subsequent mortality in a prospective study of 39 patients
with steroid-refractory chronic GVHD [36] but not in a pro-
spective, multicenter, observational cohort composed of 283
chronic GVHD cases [39]. The association of response with
subsequent overall survival might depend on patient or
disease characteristics or on the context of ﬁrst-line versus
subsequent treatment. In a study of ﬁrst-line treatment,
complete response or complete plus partial response by a
wide variety of deﬁnitions at 6 months did not correlate with
subsequent resolution of the disease and successful with-
drawal of systemic treatment [40].
Although complete response clearly provides clinical
beneﬁt, the extent to which partial response also provides
clinical beneﬁt is less clear. Several approaches could be used
to increase the likelihood that response is associated with
clinical beneﬁt. First, the beneﬁt of partial response could beTable 3
Characteristics and Beneﬁts Demonstrated to be Associated with Proposed Endpoi
Proposed Endpoint Characteristics Associated Beneﬁts
Objective,
Reliable,
Veriﬁable
Simplicity Decreased
Symptom Burden
Better F
Response Yes No Yes Yes
FFS No* Yes Mixed NT
SWOPI Yes No Yes Yes
PROs Yes Yes Yes Yes
Composite scale Yes No Yes Yes
NT indicates not tested.
* Decisions to change treatment are not adequately objective or reliable.enhanced if the deﬁnition included a requirement to
demonstrate improvement in the most severe manifestation
of chronic GVHD. Second, the stringency and reliability of
criteria for partial response would be enhanced if the deﬁ-
nition required an improvement across 2 categories of
severity in a 4-point scale (eg, from 4 to 2 or from 3 to 1)
instead of 1 category (eg, from 4 to 3, 3 to 2, or 2 to 1). Third,
clinical beneﬁt might be more apparent when response is
measured at 12 months instead of 6 months. Studies
analyzing data prospectively collected in a standardized
manner could be used to test these hypotheses.
Failure-Free Survival
For this endpoint, “failure” has been deﬁned as death,
recurrent or progressive malignancy, or the initiation of new
systemic treatment for chronic GVHD [24,41]. Increased
dosing of existing treatment is not considered as failure. Thents
unction Shorter Time to Durable GVHD
Resolution and Withdrawal of
Systemic Treatment
Improved Overall Survival
No Inconsistent
Yes Yes
NT NT
NT Some
NT NT
Table 4
Clinician-Reported Measures as Potential Indicators of Beneﬁt in Clinical Trials
Lead Author
and Reference
Clinician-Reported Measures Gold Standard Study Design Comments Results
Mitchell [27] Full 2005 NIH spectrum of measures by
transplant clinicians
Subspecialty experts 25 children and adults with chronic GVHD (4
consecutive pilot trials)
Supports feasibility of the NIH measures.
Inter-rater agreement for skin and oral was
satisfactory except for moveable sclerosis and
moderate to substantial for functional capacity,
gastrointestinal, and global rating measures.
Jacobsohn [28] NIH skin score Clinician and patient perception of skin
improvement or worsening,
Overall survival
N ¼ 458 prospective multicenter longitudinal
observational cohort study
The 0-3 NIH composite skin score correlated
with both clinician and patient perception of
improvement or worsening. Worsening skin
score at 6 months was associated with worse
survival.
Inamoto [29] NIH eye score Clinician and patient perception of eye
symptom change
N ¼ 387 prospective multicenter longitudinal
observational cohort study
Among all scales, changes in the NIH eye scores
showed the greatest sensitivity to symptom
change reported by clinicians or patients.
Schirmer’s test did not correlate.
Treister [30] NIH oral score and modiﬁed OMRS
(0-15)
Patient and clinician-reported change in oral
chronic GVHD
N ¼ 458 prospective multicenter longitudinal
observational cohort study
The clinician-reported measurement changes
most predictive of perceived change by
clinicians and patients were erythema, extent of
lichenoid changes, and NIH severity score.
Palmer [31] NIH lung score symptom scale NRM, OS, patient-reported lung symptoms N ¼ 496 prospective multicenter longitudinal
observational cohort study
The NIH symptom-based lung score was
associated with NRM, OS, patient-reported
symptoms, and functional status. Worsening of
NIH symptom-based lung score over time was
associated with higher NRM and lower survival.
Inamoto [32] NIH joint-fascia score, Hopkins scale,
photographic (P-ROM)
Clinician and patient perception of change N ¼ 567 prospective multicenter longitudinal
observational cohort study
Changes in the NIH scale correlated with both
clinician- and patient-perceived improvement.
Changes in all 3 scales correlated with clinician-
and patient-perceived worsening, but the P-
ROM scale was the most sensitive.
Bassim [33] NIH modiﬁed OMRS (0-15) Established measures of oral pain, oral function,
oral-related QOL, nutrition and laboratory
parameters.
N ¼ 198 prospective cross-sectional
observational cohort study (moderate-to-
severe chronic GVHD)
This study supports the use of the OMRS and its
components (erythema, lichenoid, and
ulcerations) to measure clinician-reported
severity of oral chronic GVHD.
No associations were found between mucoceles
and any indicator evaluated.
Curtis [34] 18 clinician-reported (“Form A”)
measures
Concurrent parameters: NIH global score,
chronic GVHD activity, Lee symptom score and
SF-36 PCS
N ¼ 193 prospective cross-sectional
observational cohort study (moderate-to-
severe chronic GVHD)
4-point and 11-point clinician reported global
symptom severity scores are associated with
most concurrent outcomes. Skin erythema is a
potentially reversible sign of chronic GVHD that
is associated with survival.
Yanik [35] Response was deﬁned as 10% FEV1
or FVC improvement
5-year survival 34 patients with subacute pulmonary
dysfunction (25 obstructive) received
etanercept therapy
5-year survival 90% (95% CI, 73%-100%) for 10
patients who responded to therapy, compared
with 55% (95% CI, 37%-83%) for the 21 patients
who did not meet response criteria (P ¼ .07).
Olivieri [36] NIH criteria, NIH organ score,
Couriel criteria
OS N ¼ 40, phase II prospective study of imatinib
for steroid-refractory chronic GVHD
The 3-year OS was 94% for patients responding
at 6 months and 58% for nonresponders
according to NIH response criteria (P ¼ .007).
BMT CTN 0801
(unpublished)
NIH criteria Clinician-assessed overall complete response þ
partial response
N ¼ 151, randomized phase II multicenter trial AUC for organs (lichenoid mouth, joint score)
plus clinician-assessed 0-10 global rating
scale ¼ .79.
NRM indicates nonrelapse mortality; P-ROM, photographic range of motion; OMRS, Oral Mucosa Rating Scale; QOL, quality of life; SF-36 PCS, Medical Outcomes Study Short Form-36; FEV1, forced expiratory volume in 1 second;
FVC, forced vital capacity; CI, conﬁdence interval; AUC, area under the curve.
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was adequately controlled in cases where no new systemic
treatment was given and that GVHD was not adequately
controlled in cases where new systemic treatment was given.
Results of retrospective studies showed that for both ﬁrst-
line and second-line treatment, the preponderant cause of
failurewas the initiation of new systemic treatment, whereas
death and recurrent malignancy accounted for only a small
proportion of failures.
The absence of death and recurrent malignancy as com-
ponents of FFS are presumed to reﬂect clinical beneﬁt. In a
landmark analysis, the absence of new treatment within 12
months after ﬁrst-line treatment or within 6 months after
second-line treatment was associated with a higher subse-
quent probability of cure of chronic GVHD but not with
improved subsequent overall survival [24,41]. A time-
dependent Cox proportional hazards analysis showed that
administration of second-line treatment is associated with
an increased risk of nonrelapse mortality compared with
continued ﬁrst-line treatment [42]. Data from a prospective
longitudinal observational study have suggested that pa-
tients with FFS at 1 year have measurable overall reductions
in symptom burden, disease activity, and functional impair-
ment compared with baseline (see online supplement).
Other evidence supports the clinical beneﬁt associated with
FFS when the prednisone dose at the endpoint assessment
time is taken into account. Lower prednisone doses were
associated with higher subsequent probabilities of durably
controlling and curing the disease [24,41] and lower death
rates (see online supplement).
Several problems remain to be addressed with the use of
FFS as the primary endpoint in clinical trials. First, new
treatment decisions are not always driven by lack of efﬁcacy.
In particular, new treatment introduced as a replacement for
an investigational product that has caused toxicity con-
founds any subsequent assessment of efﬁcacy of the inves-
tigational product. Ideally, the use of an investigational
product should be developed sufﬁciently in phase II studies
to minimize the incidence of treatment discontinuations
because of toxicity in a pivotal trial. Second, new treatment
decisions are subject to bias, making this primary endpoint
inadequate for regulatory purposes. As an alternative
approach that could address both problems, prespeciﬁed
criteria generally accepted as indicating a need for new
treatment could be used as an objective endpoint, regardless
of whether treatment had been changed or not. Third,
additional studies in other cohorts are needed to conﬁrm the
clinical beneﬁt of FFS or any alternative approach using
prespeciﬁed criteria as an objective endpoint.
Survival Without Progressive Impairment
As discussed above, treatment of chronic GVHD is inten-
ded to produce a sustainable beneﬁt by reducing symptom
burden, controlling objective manifestations of disease,
preventing organ damage and progressive impairment
leading to disability, and improving overall survival while
avoiding disproportionate toxicity related to treatment. The
term “progressive impairment” is intended to capture the
emergence of any enduring chronic GVHD-related manifes-
tation that threatens or compromises a patient’s physical
well-being or function inways that cannot be easily reversed.
Hence, progressive impairment indicates inadequately
controlled chronic GVHD.
The 2014 Response Criteria Working Group Report
deﬁned criteria for progression in the various manifestationsof chronic GVHD [14]. Some of these criteria clearly represent
progressive impairment, whereas others do not. The criteria
for progression of the NIH skin score, eye score, NIH joint and
fascia score, photographic range of motion score, NIH lung
symptom score, upper and lower gastrointestinal scores, and
esophagus score and decrease in percent predicted forced
expiratory volume in 1 second lung function test all repre-
sent progressive impairment. Certain other manifestations,
such as the development of persistent oral ulceration that
interferes with oral intake and vaginal involvement that in-
terferes with sexual function, could also be considered as
progressive impairment. In contrast, progression deﬁned
according to skin itching, the chief eye complaint, the oral
mucosal scale, oral sensitivity, liver function tests, or global
rating scales would not necessarily indicate progressive
impairment because they are more easily reversed. In many
instances, such progression can be managed by topical
treatment or by increasing the dose of prednisone.
The proposed use of SWOPI as the primary endpoint in
chronic GVHD treatment trials is based on the premise that
products cannot prevent progressive impairment unless they
also reduce symptom burden and control objective mani-
festations of chronic GVHD. Conversely, the clinical value of
products that reduce symptom burden and control objective
manifestations of chronic GVHD in the short term would be
considerably diminished if they could not also prevent pro-
gressive impairment in the longer term. SWOPI is concep-
tually similar to PFS in oncology trials by focusing on the
absence of progression as the primary measure of success.
This endpoint would be highly relevant for patients with far
advanced chronic GVHD that has continued to progress
despite the use of multiple systemic treatments for many
years. Durable prevention of further impairment without
treatment-related toxicity would have considerable value,
even if systemic treatment cannot be withdrawn.
Methods for measuring progressive impairment are not
fully developed (see online supplement). Rates of provi-
sionally deﬁned SWOPI events in a mixed cohort of currently
treated incident and prevalent chronic GVHD cases were
high, demonstrating considerable room for improvement
(see online supplement). The advantage of an investigational
product could be demonstrated if its use prevents progres-
sive impairment more effectively than the standard of care.
The use of SWOPI as an endpoint has the advantage that it is
unaffected by temporary improvement or worsening of
reversible disease manifestations associated with changes in
steroid dose or topical treatment (Figure 1).
Further work is needed to establish agreement that each
component in a deﬁnition of progressive impairment truly
indicates reliably measured harm, that chronic GVHD is the
most likely cause, and that important components have not
been omitted. Patient input should be incorporated into the
selection of these components. If a PRO instrument is used,
assessment of symptoms by the patient should not include
signs or other determinations that would be best made by a
clinician, and the clinician’s assessment should not include
symptoms that would be most reliably reported by the pa-
tient. A SWOPI endpoint has the potential to include adverse
events that could confound the interpretation of efﬁcacy.
Instruments should distinguish impairment caused by the
disease per se from those caused by the investigational
product or by an interaction of the product with chronic
GVHD.
Additional work is also needed to characterize the clinical
beneﬁt associated with SWOPI by determining whether
P.J. Martin et al. / Biol Blood Marrow Transplant 21 (2015) 1343e13591352progressive impairment is correlated with increased symp-
tom burden and disease activity. Studies should evaluate
whether SWOPI predicts improved overall survival or earlier
resolution of chronic GVHD and withdrawal of systemic
treatment, although this association is not a requirement for
determining clinical beneﬁt. Consistency of effect should also
be assessed in prespeciﬁed subsets of patients with speciﬁc
manifestations of chronic GVHD. Data from these studies are
needed to identify subsets of patients characterized by
higher and lower risks of progressive impairment and to
determine the relationship between the duration of follow-
up after enrollment and the magnitude of clinical beneﬁt
associated with SWOPI. Such data from an early-phase trial
would be very useful for sample size considerations in
pivotal trials.
As discussed in the FDA’s guide to industry regarding
endpoints [43], the frequency of assessment and missing
data can complicate the use of a PFS-like endpoint in a time-
to-event analysis. Use of PFS as a clinical endpoint for a
regulatory decision must be meaningful for the particular
study population. Whether this endpoint is meaningful de-
pends on its relevance to the direct clinical beneﬁt, magni-
tude of the effect, and the riskebeneﬁt of treatment with the
investigational product as compared with available
therapies.
Patient-Reported Outcomes
Incorporation of the patient experience into endpoints for
clinical trials addresses the “living better” component of
“clinical beneﬁt.” For a disease such as chronic GVHD, quality
of life and symptoms may reﬂect disease activity, residual
effects of GVHD, or the side effects of medications used to
treat GVHD. The FDA released draft guidance for qualiﬁcation
of PRO instruments [44] that outlines steps necessary to
consider a PRO instrument adequate to measure clinical
beneﬁt for purposes of regulatory approval.
Growing evidence supports the validity of PRO in-
struments in clinical trials of treatment for chronic GVHD.
The Lee Symptom Scale is a 30-item, 7-domain symptom
scale that has proven reliable, valid, and sensitive to change.
This scale was developed with patient input and was tested
in a cohort of 107 patients with active chronic GVHD who
completed the questionnaire every 3 or 6 months. Psycho-
metric properties were published [45]. Subsequent studies
have shown that changes in the NIH eye, skin, mouth,
gastrointestinal, and summary scales have correlated with
patient- and clinician-reported changes in chronic GVHD
activity [29,30,38,46]. Although most symptoms are speciﬁc
to chronic GVHD activity, the interpretation of changes may
be confounded by adverse side effects of treatment or side
effects of transplantation independent of chronic GVHD. In
addition, most trials of chronic GVHD treatment are not
blinded, raising concerns about the validity of PROs that can
be affected by patient beliefs that an active drug is being
administered. Further, the credibility of the analysis may be
confounded by missing data and patient dropouts.
The only other chronic GVHD-speciﬁc scale is the MD
Anderson Chronic GVHD Symptom Scale, published only in
abstract form, andmodeled after theMDAnderson Symptom
Inventory [47]. To date, almost no work in chronic GVHD has
used the Patient Reported Outcomes Measurement Infor-
mation System instruments [48].
Multidimensional health-related quality of life in-
struments, such as the Medical Outcomes Study Short Form
36 [49,50] and the Functional Assessment of CancerTherapyeBone Marrow Transplantation Subscale [51,52],
have been used in many trials. In general, these instruments
are able to detect differences according to the occurrence of
chronic GVHD [53], severity of chronic GVHD [54], and
change in chronic GVHD activity as reported by patients and
clinicians [55] but not when compared with 2005 NIH
calculated responses [38]. NIH-calculated responsemeasures
capture changes of value or importance to clinicians, but the
extent to which they do so for patients has not been deﬁned.
Many multidomain health-related quality of life instruments
lack sensitivity to changes in speciﬁc syndromes associated
with disease states. In addition, these instruments are sen-
sitive to personality traits. Table 5 provides details from
studies addressing PRO sensitivity to change in patients with
chronic GVHD.
A PRO assessment would be useful in characterizing
clinical beneﬁt andmight be acceptable as a key secondary or
coprimary endpoint to measure the core disease-related
symptoms of chronic GVHD. Investigators are encouraged
to work closely with regulatory authorities in deﬁning spe-
ciﬁc PRO measures proposed as key secondary or coprimary
endpoints in clinical trials. The FDA guidance for qualiﬁcation
of PRO instruments will assist the development, selection, or
modiﬁcation of a well-deﬁned and reliable PRO assessment
intended to support labeling claims of treatment beneﬁt
[44]. The sample size is driven by the proposed labeling
claims and should therefore account for any key secondary
endpoints needed for approval.
Composite Scale
Validated scales that incorporate clinician assessments
(eg, on a 0 to 10 or global scale or organ measures), PROs (eg,
symptoms or quality of life), and laboratory or functional
measures (eg, C-reactive protein) have been used as the
primary endpoints in registration trials for other immune-
mediated diseases such as lupus [57-63], Crohn’s disease
[64,65], ankylosing spondylitis [66], and rheumatoid arthritis
[67,68]. These scales were generally developed by identifying
clinical, laboratory, and patient-reported parameters associ-
ated with reported perceptions of change or changes in
management (eg, adding or decreasing immunosuppressive
treatment).
No such composite scale exists for chronic GVHD (see
online supplement). The value of including a variety of
measures reﬂecting different aspects of a disease process is
codiﬁed in the Outcomes Measures in Rheumatology
(OMERACT) effort [69,70]. The OMERACTconsensus initiative
speciﬁes the process of identifying a core set of measures
that should be included in any randomized controlled trial or
long-term observational study in a rheumatologic disease,
including incorporation of the patient perspective from the
start of the process. The framework includes 4 areas: death,
life impact, resource utilization, and pathophysiological
manifestations. Life impact is generally assessed by PROs,
and pathophysiological manifestations are measured by
physical exam or laboratory testing. The OMERACT ﬁlter re-
quires that 1 measure in each area be identiﬁed as a core
measure.
No gold standard anchor has been deﬁned in assessing a
composite scale endpoint for trials of treatment for chronic
GVHD. Whether a proposed composite scale endpoint would
need to be qualiﬁed against a gold standard would depend
on the individual components, the intended population, and
the context in which it is to be used. Different composite
scales may be needed for different patient populations, and
Table 5
PRO Sensitivity to Change
Lead Author
and Reference
Patient-Reported Measure Gold Standard Study Design Comments Results
Global
Pidala [55] SF-36, FACT-BMT Change in global severity, clinician-
reported, patient-reported change
N ¼ 336, correlation of change scores with
response measures in an observational study
Patient-reported severity change was associated with all
QOL measures. Change in NIH and clinician-reported
chronic GVHD severity did not correlate well with patient-
reported QOL changes.
Inamoto [38] SF-36, FACT-BMT, Lee symptom scale NIH-calculated overall response N ¼ 258, correlation of change scores with
NIH-calculated overall response in an
observational study
NIH calculated overall responses were associated with
patient-reported symptoms in patients enrolled within 3
months of chronic GVHD onset but not in patients enrolled
more than 3 months after onset. SF-36 and FACT-BMT
changes were not associated with NIH-calculated responses
regardless of time since onset.
Walker [56] SF-36, FACT-BMT, Lee symptom scale N/A N ¼ 203, randomized, unblinded study of
thymoglobulin vs. no thymoglobulin,
comparing PROs between randomized groups
The study met its primary endpoint: freedom from
immunosuppressive treatment at 12 months (37.4% vs.
16.5%, P ¼ .001). GVHD symptoms were lower in patients
randomized to Thymoglobulin (14.95 vs 20.93, P ¼ .017).
The difference was also clinically meaningful, deﬁned via
the distribution method as .5 SD.
Organ-speciﬁc
Inamoto [29] 0-10 eye symptom, Lee eye
symptom score, OSDI
Patient and clinician-reported change in
eye chronic GVHD (8-point scale)
N ¼ 387, correlation of PRO change scores
with reported response in an observational
study
Change in the Lee eye symptom score, 0-10 eye symptom,
and OSDI correlated with patient- and clinician-reported
change.
Jacobsohn [28] Lee skin symptom score NRM, OS, patient- and clinician-reported
change (8-point scale)
N ¼ 458, correlation with outcomes and
reported change in an observational study
Change in the Lee skin symptom score correlated with
patient- and clinician-perceived changes. Improvement in
the Lee skin symptoms score at 6 months was associated
with lower NRM and better OS.
Treister [30] Lee mouth and nutrition symptom
scores, patient mouth sensitivity,
pain, dryness 0-10
Patient- and clinician-reported change in
oral chronic GVHD (8-point scale)
N ¼ 458, correlation with reported change in
an observational study
In multivariate modeling, change in patient-reported Lee
mouth symptom score was associated with patient- and
clinician-reported change.
Inamoto [32] Lee muscle/joint symptom score,
global GVHD severity 0-10,
SF-36, FACT-BMT
Patient- and clinician-reported change in
joint chronic GVHD (8-point scale)
N ¼ 567, correlation with reported change in
an observational study
Change in the Lee muscle/joint symptom score, overall
symptom score, and 0-10 global score correlated with
patient-reported improvement and worsening of joint
GVHD and clinician-reported worsening of joint GVHD. SF-
36 PCS correlated with patient- and clinician-reported
improvement in joint GVHD; FACT-G correlated with
patient- and clinician-reported worsening in joint GVHD.
Inamoto [38] Lee symptom scale, mouth, eye,
skin 0-10 symptoms
NIH-calculated organ-speciﬁc change N ¼ 258, correlation with NIH-calculated
organ changes in an observational study
NIH-calculated organ responses were associated with
patient-reported symptom change in skin, eye, mouth, and
gastrointestinal tract (nutrition).
FACT-BMT indicates Functional Assessment of Cancer Therapy, Bone Marrow Transplantation subscale; N/A, not applicable; SD, standard deviation; OSDI, ocular surface disease index; FACT-G, Functional Assessment of Cancer
Therapy - General.
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adjusted as new drugs alter the course of the disease.
Demonstration of a survival beneﬁt might be expected from
effective treatment in a subgroup with relatively short
overall survival, whereas demonstration of clinical beneﬁt
through clinical response or a PRO might be more appro-
priate for patients who live longer with a potential for
chronic GVHD-related impairment. Several steps may be
needed to reach the ultimate goal of showing that a com-
posite scale correlates with the longer term goals of pre-
venting disability and controlling the disease until systemic
treatment can be withdrawn.
Given the complexity of developing a composite scale, it
would be preferable to identify simple endpoints wherever
possible and to prespecify the other measures as additional
secondary endpoints to test for internal consistency. A
composite endpoint would certainly be acceptable for reg-
ulatory purposes if each component could be justiﬁed, but
sample size considerations or studies of individual patient
populations may warrant a simpler endpoint or coprimary
endpoints instead. CROs and PROs that are well deﬁned and
reliable in the intended population and context may be
relevant measures of clinical beneﬁt on their own.
KEY CONSIDERATIONS FOR THE DESIGN OF CLINICAL
TRIALS
Although the deﬁnition and characterization of primary
endpoints that indicate clinical beneﬁt represent urgent
goals for the immediate future, many other key consider-
ations apply in the design of clinical trials for treatment of
chronic GVHD. Many of these considerations were addressed
in the 2006 Design of Clinical Trials Working Group Report.
The following sections address some key considerations that
merit further elaboration based on experience and progress
during the past decade.
How are Lines of Treatment Deﬁned?
First-line treatment is deﬁned as the beginning of sys-
temic treatment for chronic GVHD, typically with NIH
global level 2 severity. Treatment generally involves the
introduction of prednisone or an increase in the dose to
.5 mg/kg/day, with or without the introduction or
continued administration of other agents. Subsequent lines
of treatment are most clearly deﬁned by the introduction
of any systemic agent not previously used in the regimen
for ﬁrst-line treatment. Dose adjustments of nonsteroidal
medications used for any given line of treatment are
typically not considered as the beginning of the next line of
treatment.
The question of whether steroid dose adjustments should
be considered as evidence of treatment failure or deﬁned as
the beginning of a new line of treatment has not been
entirely resolved. In retrospective studies, temporarily
increased prednisone doses up to 1 mg/kg/day were not
considered as treatment failure or the beginning of a new
line of treatment, and prespeciﬁed threshold doses of pred-
nisone at deﬁned time points after starting treatment were
used as a component in composite endpoints. Although
endpoint results from these studies could be used as
benchmarks for early-phase single-arm trials, the interpre-
tation of prospective study results would be confounded by
potential bias in the management of steroid dosing.
Compliance with rigid dosing and tapering schedules for
administration of steroids is not feasible in GVHD treatment
trials. Therefore, clinical protocols should allow someﬂexibility in the management of steroid administration. For
example, trials for ﬁrst-line treatment have allowed tempo-
rary escalation of prednisone doses up to 1 mg/kg/day
without necessarily designating such events as treatment
failure, even in situations where the disease could be cate-
gorized as steroid-refractory or steroid-dependent. Trials for
second-line and subsequent treatment have allowed re-
escalation up to the dose administered at enrollment in the
trial or up to a prespeciﬁed dose that would be considered
consistent with standard management principles.
The working group discussed several different ap-
proaches for deﬁning treatment failure and the beginning of
a new line of treatment based on changes in steroid dosing.
In ﬁrst-line treatment trials, increased prednisone dosing up
to 1 mg/kg/day could be allowed without designating these
events treatment failures, based on the argument that ﬂares
of chronic GVHD are inevitable if steroid doses are tapered
too rapidly. In trials for second or subsequent lines of treat-
ment, increased prednisone doses could be allowed as long
as they do not exceed the dose at the time of enrollment or
do not exceed a threshold speciﬁed in the protocol. In trials
with a primary endpoint to be assessed at 6 to 12 months
after enrollment, a brief pulse of steroid treatment early in
the trial could be allowed if needed, but the protocol would
have to specify the maximum steroid dose, duration of ste-
roid administration, and number of pulses, together with the
maximum interval time from enrollment.
The guidelines for determining eligibility for second-line
treatment trials based on inadequate response to steroid
therapy would logically apply in deﬁning failure of ﬁrst-line
treatment based on steroid dose changes alone. For
example, an increase in the prednisone dose because of
persistent manifestations that are not improving despite 4
weeks of treatment at >.5 mg/kg/day or an increase in the
prednisone dose to >.25 mg/kg/day after 2 unsuccessful
attempts to taper the dose to lower levels could be
considered as treatment failures, because these circum-
stances would make a patient eligible for second-line
treatment. Results in trials for second and subsequent
lines of treatment would be most informative if no increase
in the steroid dose is allowed within a deﬁned period of
time before enrollment or at the time of enrollment and if
any subsequent increase in the steroid dose above the
baseline is interpreted as treatment failure and the begin-
ning of a new line of treatment.
Taken together, these considerations emphasize the need
for clarity in the deﬁnitions of eligibility criteria and end-
points with respect to changes in steroid dosing in designing
clinical trials. The complex vagaries of decision-making
related to steroid dosing emphasize the value and impor-
tance of controlled designs with blinding in pivotal trials.
What Speciﬁc Considerations Apply for First-Line
Treatment Studies?
Most ﬁrst-line trials involve treatment with steroids and
an investigational product in single-arm trials and steroids
with or without an investigational product in controlled
trials. All protocols should specify the following: (1) whether
administration of prestudy treatments should be dis-
continued or continued when patients are enrolled in the
study, (2) whether steroid doses may be changed or new
topical agents added at the time of enrollment, (3) whether
steroid doses may be increased above the baseline dose after
enrollment, and (4) whether new topical agents may be
added after enrollment. The protocol should deﬁne the initial
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the dose of steroids and the sequence in relation to other
treatments. The protocol should also provide guidelines for
the subsequent withdrawal of other GVHD treatment medi-
cations, including the investigational product.
What Speciﬁc Considerations Apply for Second and
Subsequent Lines of Treatment?
Single-arm phase I or II trials have been used for the initial
evaluation of systemic agents for treatment of chronic GVHD
that has not been adequately controlled with steroid treat-
ment. Phase II randomized controlled trials may also be
considered. Patients in the control arm should be treated
with an accepted standard of care. Eligibility for phase I trials
depends on the anticipated toxicity and efﬁcacy proﬁles of
the investigational product. For evaluation of potent and
potentially toxic immunosuppressive agents, eligibility
should be restricted initially to patients with advanced
steroid-refractory chronic GVHD.
In addition to the ﬁrst 4 considerations for ﬁrst-line
treatment studies, all protocols for second and subsequent
lines of treatment should specify the following: (1) whether
both second and subsequent lines of treatment are allowed,
(2) the minimum interval time from the most recent change
of systemic treatment to enrollment, and (3) the types and
timing of recent treatment changes that are allowed with
respect to steroid dosing and the use of topical agents. These
considerations are particularly important in studies of pa-
tients with sclerotic manifestations, where improvement
might not occur until several months after starting
treatment.
In single-arm early-phase trials for second-line or sub-
sequent treatment, eligibility criteria may be narrowed to
improve homogeneity in baseline characteristics of the study
cohort, thereby facilitating informal comparisons with re-
sults of other single-arm trials. In contrast, eligibility criteria
in controlled early-phase trials may be deﬁnedmore broadly,
depending on the anticipated target population for later
pivotal trials.
For Response-Based Endpoints, What Reasons for
Beginning New Systemic or Topical Treatment Should be
Considered as Failure in the Analysis of Response-Based
Endpoints, and What Reasons Should be Allowed without
Being Considered as Failure?
The protocol should deﬁne the extent to which changes
in concomitant treatment with systemic and topical agents
are allowed at baseline and subsequently. Response-based
endpoints are likely to be confounded when such changes
in topical or systemic treatment are allowed. Reasons for
adding new systemic treatment should always be recorded.
The protocol should specify how response would be
assessed when such changes are made. Addition of new
systemic treatment because of worsening disease manifes-
tations should always be counted as progression in a
response endpoint. Pre-emptive addition of new systemic
treatment before the response assessment to prevent pro-
gression after treatment with an investigational product has
been discontinued in a patient with stable disease mani-
festations should also be counted as progression. Likewise,
addition of new systemic treatment before the response
assessment because improvement has halted should also be
assessed as progression in a response endpoint, although
efforts should be made to minimize such changes in therapy,
if possible.What is the Timeframe for Expecting Responses with
Various Manifestations of Chronic GVHD?
The expected minimal time for response varies and
depends on the speciﬁc manifestation. Improvement is ex-
pected to occur within 4 to 8 weeks for inﬂammatory man-
ifestations such as erythema, edema, transaminase elevation,
and diarrhea. Improvement of established sclerosis takes at
least 6 months to a year but may occur within 3 months for
early inﬂammatory fasciitis manifested as edema and
tenderness with decreased range of motion without ﬁxed
joint contractures.
What Manifestations of Chronic GVHD Should be
Considered as Irreversible for Purposes of Measuring
Response?
Advanced ﬁbrosis, sclerosis, adnexal loss, bronchiolitis
obliterans, and destruction of lacrimal and salivary glands
are often considered irreversible, although complete reso-
lution of advanced cutaneous sclerosis has been reported in
some studies [36].
Would it be Acceptable to Design a Trial that Aims Only
to Keep Chronic GVHD from Progressing or from Causing
Impairment?
Early experience showed that without treatment, chronic
GVHD will progress relentlessly toward disability and death
[19], but prolonged treatment with high-dose glucocorti-
coids can cause devastating toxicity. Development of a well-
tolerated product that could replace prednisone while
effectively and reliably preventing newly diagnosed or early
stage moderately severe chronic GVHD from progressing or
causing irreversible impairment would represent a major
step forward in the ﬁeld, even if this product did not reverse
pre-existing manifestations. The high proportion of patients
who advance to second-line treatment within the ﬁrst 2
years of ﬁrst-line treatment demonstrates that current ap-
proaches leave much room for improvement. Similarly,
development of a well-tolerated product that could prevent
advanced disease from progressing further or causing
increased impairment or disability without requiring inter-
minable treatment with high-dose prednisone would
represent a major step forward in the ﬁeld, even if it did not
reverse pre-existing manifestations. The high proportion of
patients who advance to third-line treatment within 12
months of second-line treatment demonstrates that current
approaches are far from satisfactory.
What are the Advantages and Disadvantages of
Controlled Trials versus Single-Arm Trials?
Single-arm trials cannot adequately determine the extent
to which trial results were inﬂuenced by the disease trajec-
tory before enrollment, the baseline characteristics of the
study cohort, or by any concomitant treatment started at
enrollment or added between enrollment and the endpoint
assessment. Accordingly, the treatment effect (ie, safety and
efﬁcacy) of an investigational product can be difﬁcult to
assess in single-arm trials, unless results with a homoge-
neous population of study patients can be compared with a
similarly homogeneous historical group. In most situations,
the results of a single-arm phase II trial can be used only to
determine whether an investigational product has enough
activity to warrant further investigation in a phase III trial.
Controlled trials make it possible to determine the true
treatment effect, if the prior disease trajectory, baseline
characteristics, and concomitant treatment are similar
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controlled trials, because matching for comparisons with
historical experience is not necessary. In controlled trials,
stratiﬁed randomization decreases the probability of an
imbalance in the distribution of risk factors that could affect
the primary endpoint. With any given statistical error spec-
iﬁcation, however, the required sample size is much larger
for controlled trials than for single-arm trials. In controlled
phase II studies intended only to assess the merits of a phase
III study, this disadvantage could be mitigated by allowing a
larger Type I error speciﬁcation, and in phase III studies, the
numbers of patients can be optimized by using group
sequential designs. Controlled trials are also more difﬁcult to
organize and conduct, because multicenter participation is
necessary, although multicenter participation has the
advantage of mitigating possible center-speciﬁc effects on
trial results. In addition, patients and physicians may be
reluctant to participate in controlled trials testing amarketed
product if prior experience has suggested that a readily
available investigational treatment has advantages over the
standard of care or if the known efﬁcacy of standard treat-
ment is limited.
What are the Advantages and Disadvantages of Crossover
Designs?
Crossover designs can be used to compare initial out-
comes of treatment with an investigational product versus
the standard of care or with 2 different investigational
products. To some extent, crossover designs overcome the
limitations of single-arm designs by allowing results with 2
different types of treatment to be compared. Crossover de-
signs also afford all patients an opportunity to be treated
with an investigational product. Randomized crossover de-
signs enable a robust interpretation of results up to the
crossover point, but the interpretation of outcomes after the
crossover point is confounded by the prior treatment. Blin-
ded designs are critically important to prevent bias in
crossover decisions.
What are the Advantages and Disadvantages of Delayed
Start Designs?
Delayed start designs can be used to document the tra-
jectory of disease manifestations before beginning treatment
with an investigational product. For example, serial moni-
toring of pulmonary function test results in a delayed start
study could determine whether treatment with an investi-
gational product changes the progression of bronchiolitis
obliterans in the absence of a control group. In these studies,
the criteria that trigger the onset of treatment must be
deﬁned in a way that allows unambiguous demonstration of
progression or prolonged stability, without risking harm
caused by unduly delayed treatment.
What are the Advantages and Disadvantages of
Composite Endpoints?
Composite endpoints make it possible to encompass
several different measures of clinical beneﬁt associated with
the primary endpoint of a trial. Each component of a com-
posite endpoint must have demonstrable clinical beneﬁt. The
individual components of composite endpoints may have
large differences in the extent to which they indicate clinical
beneﬁt, thereby making composite endpoints more difﬁcult
to interpret as comparedwith simple endpoints. A composite
endpoint affords greater sensitivity to detect treatment fail-
ure, especially if the components address different aspects ofthe disease. Comparisons among different studies could be
facilitated by reporting standardized composite endpoints
that reﬂect key aspects of disease activity.
Do Placebos Have Any Role in Controlled Trials of
Treatment for Chronic GVHD?
Placebos could be used for 2 purposes. In trials testing the
effect of adding a second agent to the standard of care, a
placebo can be used to blind of the arm assignments. In this
situation, the blinded study product is not a placebo in the
true sense of the word, because patients in the control arm
are treated with an active standard of care. Placebos could
also be used in trials testing the effects of treatment in pa-
tients with stable disease manifestations that do not need
immediate intervention.
What Speciﬁc Considerations Apply When Clinical Trial
Results Will be Submitted for Regulatory Review?
Trials submitted for regulatory review require a meticu-
lous statistical analysis plan that will support the proposed
labeling claims, together with extensive detail in doc-
umenting adverse events and the use of concomitant medi-
cations. In other respects, the design and conduct of clinical
trials should be based on good clinical science and not be
inﬂuenced by plans for regulatory review.
LESSONS FROM REGULATORY REVIEW OF TREATMENT
FOR OTHER DISEASES
Two large-scale reviews of decisions by the FDA offer
insights for the design and conduct of studies intended for
regulatory review [71,72]. The ﬁrst report characterized
pivotal efﬁcacy trials that provided the basis for approval of
novel therapeutic agents between 2005 and 2012 [71].
Among the 448 trials, 36 were intended for 13 indications
related to autoimmune and musculoskeletal diseases, the
category most closely related to chronic GVHD. All these
trials had randomized control designs, 34 (94%) were
double-blinded, 11 (31%) had active comparators and 25
(69%) had placebo comparators, 28 (78%) had clinical scale
endpoints, 6 (17%) had surrogate endpoints such as labora-
tory measures, and 2 (6%) had clinical endpoints such as
death, hospitalization, or functional measures. A median of
525 patients were enrolled, and participation extended
beyond 6 months in 12 studies (33%). Approvals for the 13
indications in this category were based on studies that
enrolled an aggregate median of 1209 patients with an
aggregate median of 1955 patients in the safety population.
Among the 13 indications, 11 approvals (85%) were based on
at least 2 studies and only 2 (15%) were based on a single
trial.
The second report characterized reasons for disapproval
of new drug applications between 2000 and 2012 [72]. As
summarized in an accompanying editorial [73], the results
indicate that in reviewing clinical trials, the FDA is looking for
evidence of generalizable study populations, adequate sam-
ple size, meaningful health outcomes and degree of inﬂuence
on those outcomes, consistency of multiple endpoints
among different trials and sites, improvement over the
standard of care, and evidence that beneﬁts exceed harms.
Enrollment of a sufﬁcient sample size poses the most
difﬁcult challenge in conducting trials for treatment of
chronic GVHD. The largest trial to date enrolled 287 patients
[9]. Two multicenter trials took 4 years to enroll 151 patients
in each (Paul Carpenter, personal communication, April 2014,
[8]), even though both adults and childrenwere eligible. Both
P.J. Martin et al. / Biol Blood Marrow Transplant 21 (2015) 1343e1359 1357were stopped early for futility. Hence, a very large effect size
would be needed for rapid progress in developing a new
treatment for chronic GVHD.
Clinical Development Paths
In the absence of approval of any drug for treatment of
chronic GVHD, no precedent for development paths leading
to regulatory approval for this indication has been estab-
lished. Even so, some general principles have emerged from
the considerations summarized above. In this context, phase
I studies are intended primarily to identify a safe dose of an
investigational product speciﬁcally in patients with chronic
GVHD. As might be expected, the side effects of marketed
products in patients with chronic GVHD are generally similar
to those observed in patients with the approved indication,
but careful considerationmust be given to the implications of
differences in the concomitant medications that are typically
used in patients with chronic GVHD as compared with those
used in patients with the approved indication. In studies
testing marketed products for chronic GVHD as a new indi-
cation, the initial doses and schedules of administration can
be based on those for the approved indication, but pre-
liminary dose ﬁnding studies with assessment of pharma-
cokinetics, pharmacodynamics, potential drug interactions,
and adverse events may be needed. Studies testing products
in humans for the ﬁrst time would have to follow the usual
approach for determining the initial dose, frequency of
administration, and dose escalation in phase I studies.
Initial studies of treatment for chronic GVHD always
include some measure of clinical activity in controlling the
disease. For this purpose, shorter- term endpoints are pref-
erable to longer term endpoints. For example, it would be
reasonable to expect that an active product could improve
cutaneous erythema and readily reversible oral, gastroin-
testinal, and hepatic manifestations of chronic GVHD within
4 to 8 weeks after starting treatment. Much longer follow-up
is needed to determine whether a product could prevent or
reverse sclerotic manifestations of chronic GVHD. Systemic
treatment would not be expected to reverse bronchiolitis
obliterans or destruction of lacrimal and salivary glands
caused by GVHD, although certain products could relieve
symptoms caused by such damage.
Phase II studies should be designed to determinewhether
the short-term safety and activity of the product can be
conﬁrmed in a larger and potentially more diverse cohort of
patients and to assess the safety and activity of the product
with respect to the longer term goals of providing a sus-
tainable beneﬁt. The optimal primary efﬁcacy endpoint for
these studies has not yet been deﬁned and characterized.
Response deﬁnitions associated with sustainable improve-
ments in the most bothersome symptoms and overall
symptom burden, reduced disease activity, absence of pro-
gressive impairment related to chronic GVHD, and improved
survival would offer evidence of clinical beneﬁt. An impor-
tant goal of phase II studies is to estimate the size of effects
on the primary endpoint to support the design of phase III
studies. The secondary efﬁcacy endpoints in phase II studies
should be designed to explore and help characterize the
clinical beneﬁt that may be associated with the primary
endpoint both in the overall cohort and in subsets of patients
with speciﬁc manifestations of chronic GVHD. The use of
standardized instruments and time points for assessment of
efﬁcacy is essential to enable comparison of results across
multiple studies. Safety endpoints should be designed to
assess the long-term tolerability of the investigationalproduct and to identify any potential drug interactions and
dose adjustments to be considered and incorporated in a
pivotal trial.
Themost appropriate primary endpoints for a pivotal trial
remain to be deﬁned. The lowmortality risk inmany patients
with chronic GVHD would make it difﬁcult to demonstrate
survival beneﬁts in pivotal trials, given the number of pa-
tients available for such studies, and aminimum follow-up of
at least 2 to 3 years would be needed to demonstrate
improved cure rates. These considerations highlight the
importance of current efforts to characterize the clinical
beneﬁt associated with shorter term endpoints that could be
used in future pivotal trials.
CONCLUSIONS
Challenges in the design of chronic GVHD treatment trials
are much more clearly deﬁned than they were in 2005. As
emphasized throughout this report, the identiﬁcation and
characterization of primary endpoints that indicate clinical
beneﬁt represent the most urgent goals to be accomplished
within the next several years. Prospectively collected data
from well-designed observational studies and clinical trials
should be used to characterize the clinical beneﬁt associated
with a variety of proposed endpoints assessed at speciﬁc
time points. The most informative results are likely to come
from replicated analyses of cases representative of an
intended treatment population, anchored to a treatment
change and having a well-documented baseline for assess-
ment of response. Incident casesmay have less heterogeneity
and fewer irreversible diseasemanifestations comparedwith
prevalent cases, but prevalent cases are more frequent than
incident cases.
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